Alzheimer's disease drug development pipeline: 2026
Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2026-04 · 12 (2)
DOI: 10.1002/trc2.70251 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 05.05.2026. Verfasst von Jeffrey L Cummings und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine University of Nevada, Las Vegas…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Discovery and development of new therapies for Alzheimer's disease (AD) are urgently needed to address the world's growing population of individuals on the AD pathophysiological continuum. Clinicaltrials.gov is a resource for studying drugs in development for treatment of AD. RESULTS There are currently 158 drugs in 192 AD trials. Of the agents in trials, 39% are small molecule disease targeting therapies (DTTs); 34% are biologic DTTs; 18% are cognition enhancing symptom targeted therapies (STTs); and 10% are STTs being developed to treat neuropsychiatric symptoms of AD. Currently active trials require 54,728 participants of which 38,417 are in Phase 3. The biopharmaceutical industry sponsors 59% of AD trials including 72% of Phase 3 trials. Repurposed drugs represent 35% of the drugs in trials. DISCUSSION The AD drug development pipeline has a growing number of trials and drugs in trials. A diverse array of AD pathophysiological processes is being addressed by drugs in trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA.
- Department of Brain Health, Kirk Kerkorian School of Medicine University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA.
- Genomic Medicine Institute, Lerner Research Institute Cleveland Clinic Cleveland Ohio USA.
- Howard R Hughes College of Engineering, Department of Computer Science University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA.
- Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine Case Western Reserve University Cleveland Ohio USA.
- Case Comprehensive Cancer Center Case Western Reserve University School of Medicine Cleveland Ohio USA.
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Cummings, J. L., Zhou, Y., Yang, Y., Zhong, K., Fonseca, J., Osse, A. L., & Cheng, F. (2026). Alzheimer's disease drug development pipeline: 2026. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 12(2). https://doi.org/10.1002/trc2.70251
Vancouver
Cummings JL, Zhou Y, Yang Y, Zhong K, Fonseca J, Osse AL, et al. Alzheimer's disease drug development pipeline: 2026. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2026;12(2). doi:10.1002/trc2.70251
BibTeX
@article{Cummings2026,
author = {Cummings, Jeffrey L and Zhou, Yadi and Yang, Yuxin and Zhong, Kate and Fonseca, Jorge and Osse, Amanda Leisgang and Cheng, Feixiong},
title = {Alzheimer's disease drug development pipeline: 2026},
journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
year = {2026},
volume = {12},
number = {2},
doi = {10.1002/trc2.70251}
}
EUVIMED